Article Text

Download PDFPDF
Long Follow-up of Patients With Locally Advanced Cervical Cancer Treated With Concomitant Chemobrachyradiotherapy With Cisplatin and Ifosfamide Followed by Consolidation Chemotherapy
  1. Branka Petric Miše, MD*,
  2. Tihana Boraska Jelavic, MD, PhD*,
  3. Ante Strikic, MD*,
  4. Darijo Hrepic*,
  5. Krešimir Tomic, MD,
  6. Wolfgang Hamm, MD,
  7. Snježana Tomic, MD, PhD§,
  8. Tomislav Prskalo, MD* and
  9. Eduard Vrdoljak, MD, PhD*
  1. *Department of Oncology, University Hospital Split, Split, Croatia;
  2. Department of Oncology, University Hospital Mostar, Mostar, Bosnia and Herzegovina;
  3. Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany; and
  4. §Department of Pathology, University Hospital Split, Split, Croatia.
  1. Address correspondence and reprint requests to Eduard Vrdoljak, MD, PhD, University Hospital Split, Spinciceva 1, HR-21000 Split, Croatia. E-mail: edo.vrdoljak{at}gmail.com.

Abstract

Objectives Locally advanced cervical cancer (LACC) is one of the leading health problems of the developing countries. We present long-term outcomes of treatment with a concomitant chemobrachyradiotherapy followed by consolidation chemotherapy regimen.

Materials and Methods We treated 118 patients with LACC (International Federation of Gynecology and Obstetrics stages IB2-IVA) with external radiotherapy (50 Gy in 25 fractions) and concomitant chemobrachyradiotherapy (low-dose rate). Chemotherapy was applied during brachyradiotherapy (cisplatin on day 1 in combination with 24-hour infusion of ifosfamide and mesna uroprotection). Four cycles of consolidation chemotherapy were given starting 4 weeks after the second concomitant chemobrachyradiotherapy cycle.

Results After median follow-up period of 99.3 months, we observed acceptable acute and late toxicity, local control rate of 97.5%, and an overall survival of 74.6% at 96 months.

Conclusions Chemobrachyradiotherapy regimen followed by consolidation chemotherapy described in this article is a valuable treatment option for LACC.

  • Cervical cancer
  • Ifosfamide
  • Cisplatin
  • Chemobrachyradiotherapy

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.